Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Molecular targets for the rational design of drugs to inhibit SARS coronavirus

Sarah M. Brockway1,2, Mark R. Denison1,2,3,*

Despite years of research, the precise determinants of coronavirus replication and pathogenesis remain unidentified. What is known of the pathogenesis of the severe acute respiratory syndrome coronavirus (SARS-CoV) is limited, but clinical observations suggest that both viral-induced cytotoxicity and host immune-mediated destruction contribute to the severity of disease. This summary discusses recent advances in coronavirus research that will facilitate the identification of crucial molecular targets for the rational design of SARS therapeutics.

Introduction

Historically, coronaviruses have not been regarded as severe human pathogens, as illness is primarily limited to mild upper respiratory infections that comprise 20% of the annual common colds worldwide [1]. However, the recent identification of a novel human coronavirus as the etiological agent of severe acute respiratory syndrome (SARS) dramatically demonstrated the potential of this virus family to cause devastating and potentially pandemic disease, as well as economic and social disruption [2]. Although coronavirus replication and pathogenesis has been the focus of many years of research by numerous dedicated investigators, many unanswered questions remain about exactly how these viruses proliferate in the host organism and bring about disease (see Outstanding issues). Of chief importance is the question: how can we inhibit coronavirus-induced diseases such as SARS? At present, there are no clinically proven treatments for SARS, and care of infected persons has been mostly empiric. This review gives a brief description of coronavirus replication and SARS coronavirus (SARS-CoV) pathogenesis, describes the current therapies for treating SARS, and highlights recent advances in the identification of crucial molecular targets for the rational design of antivirals and therapeutics.
Main text

Disease manifestation and SARS-CoV pathogenesis

Patients diagnosed with SARS exhibit an atypical pneumonia with a lower respiratory tract infection, associated with pulmonary lesions, alveolar damage, mononuclear infiltrate and the presence of large multi-nucleated cells in the lungs. Although there have been no detailed studies of SARS-CoV pathogenesis, the clinical progression of SARS has been shown to follow a tri-phasic pattern [3]. Early-stage symptoms last approximately 7–10 days and include fever and general myalgia that is coupled with increasing viral load. At this phase, symptoms are thought to be primarily a consequence of viral-induced cytopathic effects. Mid-stage disease occurs between 10 and 14 days, revealing an increase in fever occurrence and diarrhea, and is accompanied by a slight decrease in viral load. Specific antibodies against SARS-CoV can be detected in patient sera at this stage of disease progression, suggesting that viral replication as well as host immune response might be contributing to illness. During late-stage infection a clinical worsening occurs that is associated with decreased viral shedding. Nearly 20% of patients suffer acute respiratory distress syndrome (ARDS) and require ventilatory support [3]. At late-stage infection, lung and immunopathological damage and severe lymphopenia have been proposed to be a direct result of an excessive immune response.

Because both viral replication and the host immune response are hypothesized to contribute to the pathogenesis of SARS-CoV, it is important to understand both aspects of virus biology to define potential therapeutics that combine direct antivirals and immune modulators. Viral factors influencing disease might include those that serve the sole purpose of enhancing virulence (much like toxins), as well as factors that cause cytotoxic effects on the host cell as a mere consequence of viral replication. To date, most of the individual SARS proteins have no known functions, and no potential virulence factors have been identified. Therefore, our discussion will be limited to the molecular determinants of coronavirus replication, the virus–cell interactions that occur during replication and their suspected contribution to pathogenesis, and the involvement of the immune system in enhancing the severity of coronavirus disease.

Contribution of viral-induced cytopathic effects to disease

It is not known how damage to infected cells caused by coronavirus replication impacts the severity of disease. The three main cytopathic effects of coronavirus replication on the host cell are: syncytia (multi-nucleated cell) formation, the initiation of apoptosis (programmed cell death), and the induction of cellular autophagy (degradation of intracellular components in lysosomes). For many coronaviruses, syncytia formation is a hallmark of infection during replication in cell culture. Syncytia form as a result of the cell–cell fusion caused by viral attachment proteins (Spike or S), located on the infected cell surface, binding to receptors on adjacent cells. The lung pathology of SARS patients noted the presence of syncytia, however SARS-CoV does not cause Vero (African green monkey kidney) cells to become multi-nucleated in culture [3]. It remains unknown whether this cell–cell fusion event disrupts normal cellular processes, leading to cytotoxicity. Apoptosis is another potentially detrimental effect of coronavirus replication. One report showed an increase in the number of apoptotic cells in the spleen, lung and lymph nodes of SARS patients as compared with normal tissues [4]. The apoptotic cells include pneumocytes, lymphocytes and monocytes, which despite this increase in programmed cell death were still more numerous in infected tissues. Coronavirus-induced apoptosis has been studied in greater detail for the model coronavirus mouse hepatitis virus (MHV), specifically as it relates to the demyelination of the central nervous system (CNS) in mice. One study revealed that MHV induces apoptosis of oligodendrocytes upon entry of the virus into the cell and that this process does not require ongoing viral replication [5]. Presumably, the induction of programmed cell death is mediated either by signaling via a cell surface receptor that is activated upon virus attachment and entry, or is caused directly by a component of the incoming coronavirus virion. In support of the latter, it has been shown that expression of the SARS structural protein nucleocapsid in cultured cells leads to reorganization of the actin cytoskeleton and the induction of apoptosis [6]. It is not apparent whether the initiation of apoptosis is beneficial to coronavirus replication or instead just a by-product of viral entry. By contrast, activation of the host cell autophagy pathway, which is normally involved in protein and membrane recycling, is actually required for the efficient replication of MHV [7]. MHV, and probably all coronaviruses, induces the formation of intracellular double-membrane vesicles that serve as scaffolds for viral enzymes. These double-membrane vesicles are derived from host cell autophagosomes, and inhibiting components of the autophagy pathway disrupts viral replication. MHV infection increases the amount of cellular protein degradation by activation of autophagy. Consequently, this process could have severe cytotoxic effects on cells and contribute to viral pathogenesis.

Immunological factors enhancing coronavirus pathogenesis

The capacity of a virus to modulate the immune response can have a pivotal effect on the course of disease and the fate of the infected host. The severe lung inflammation, macrophage infiltration and lymphopenia seen in SARS patients suggests that the host immune response contributes significantly to the high morbidity and mortality of SARS. Still, it is not known why the immune system is so highly induced upon infection with SARS-CoV. It is probable that the adaptive immune response plays a role in SARS pathogenesis; however,
the robust activation of the innate response, specifically inflammation, seems to be the most devastating in terms of exacerbating disease. Elevated levels of proinflammatory cytokines, chemical signals that recruit immune cells to infected tissues, have been detected in SARS-CoV-infected persons. For example, pediatric SARS patients show markedly elevated levels of the cytokine IL-1β, a primary mediator of inflammation that is also implicated in cellular apoptosis [8]. A recent study of adult SARS patients has demonstrated that as the severity of symptoms worsens, levels of the IL-6 (promotes antibody-producing B cells) increase, whereas levels of IL-8 and TGF-β (inhibits immune cell activation) decrease [9]. For MHV, innate immune responses are implicated in the neuropathology seen in infected mice. In particular, the capacity of different strains of MHV to differentially stimulate cytokine release in the CNS directs the type of infiltrating leukocyte populations and alters the severity of viral encephalitis [10]. The results of these studies support the contention that cytokine dysregulation during coronavirus infection might account, at least in part, for the severity of clinical disease.

**Current therapies used for the treatment of SARS**

To date, there are no clinically proven therapies for coronavirus infections, in animals or in humans. During the acute SARS epidemic of 2003, the severity and high mortality of the disease led to the use of numerous, and often combined empiric antiviral drugs and immune modulating therapies. Specifically, based on the clinical observations and inferences, patients infected with SARS-CoV were treated with steroids, to inhibit inflammation, and with the antiviral ribavirin, a nucleoside analog proven clinically effective for several other RNA viruses. The limitations of clinical and virological measures and the lack of controlled studies make it difficult to draw conclusions regarding the efficacy of ribavirin and steroid therapy to significantly lessen the severity of SARS. In a preliminary study, the use of interferon-alpha (IFNα) in combination with corticosteroids was associated with a more rapid resolution of radiographic lung abnormalities [11]. Interferons inhibit viral infection both by activating immune cells and by altering the intracellular environment to restrict viral replication, thus making them good candidates for therapeutics. Moreover, one study reported that the administration of human immunoglobulin from convalescent patient sera showed some clinical benefits, suggesting that antibodies against SARS-CoV might decrease viral load [12]. Known antivirals targeting the viral enzymes, such as the proteases, have also been tested as potential inhibitors of coronavirus replication. The cysteine protease inhibitor E64-d was shown to dramatically reduce SARS-CoV replication under cell culture conditions [13]. Additionally, the human immunodeficiency virus (HIV) aspartic acid protease inhibitor lopinavir–ritonavir decreased SARS-CoV replication *in vitro* and was associated with reduced morbidity and mortality in infected patients when compared with untreated individuals [14]. Based on these preliminary reports, further evaluation of both E64-d and lopinavir–ritonavir using controlled studies is warranted.

**Coronavirus replication and molecular targets for antivirals**

Our current understanding of basic coronavirus biology, based on years of research by a cadre of committed investigators, has provided a molecular basis for the design of new antivirals. Specifically, the majority of what is known concerning intracellular coronavirus replication has been determined using MHV as a model system. Although the details of SARS-CoV replication remain to be determined, the similarities between MHV and SARS-CoV at level of the replicase proteins (enzymes that replicate the viral RNA) suggests that these two viruses can have similar intracellular replicative processes [15]. Thus, what we know about MHV can be applied to the development of drugs targeting the SARS-CoV replication machinery (Table 1).

Coronavirus replication is initiated by binding of the viral attachment protein (Spike or S) to specific receptors on the surface of the host cell and entry of the viral genome (positive-strand RNA) into the cytoplasm (Fig. 1). Molecules involved in viral attachment and entry represent the first targets for inhibition of the viral lifecycle. The type of receptor utilized by different coronaviruses is the primary determinant of the capacity of these viruses to replicate within a specific cell type or tissue. For SARS-CoV, angiotensin-converting enzyme 2 (ACE-2) has been identified as a functional receptor [16]. The fact that ACE-2 is expressed in numerous tissues in the human body supports the observation that SARS-CoV has been detected in the blood, lung, liver and kidneys. One report characterized the determinants of SARS-

| Table 1. Targets for inhibiting SARS-CoV replication |
|-----------------------------------------------|
| **Stage of virus lifecycle** | **Targets** |
| Virus attachment and cell entry | Spike and ACE-2* |
| Replicase protein processing | PLPβ and 3CLproα |
| Replication complex formation | ATGSβ and replicase proteins |
| RNA synthesis | RdRpα, Heβ and replicase proteins |
| Delivery of RNA to assembly sites | Heβ and nucleocapsid |
| Virion particle assembly | Viral structural proteins and cellular ERβ proteins |
| Virion release from the cell | Viral structural proteins and exocytosis proteins |

*a* Angiotensin-converting enzyme-2, a cellular receptor for SARS-CoV [16].

β Papain-like protease.

α 3C-like protease.

β Autophagy Gene 5.

ε Viral RNA-dependent RNA polymerase.

γ Viral helicase.

Δ Endoplasmic reticulum.
CoV entry into cells and the three-dimensional crystal structure of Spike, the viral attachment protein, has been solved [17,18]. These studies provide the blueprints for the development of inhibitors of viral entry, probably targeting the Spike glycoprotein or the viral receptor ACE-2.

Following entry of the genome RNA molecules into the cytoplasm, the next stage in the virus lifecycle is generation of the viral proteins required for RNA synthesis. Enzymes or proteins involved in the synthesis of viral RNA can, in theory, be inhibited without detrimental effects on the host cell and are thus ideal targets for antivirals. Coronaviruses generate proteins required for viral RNA synthesis first as a large polyprotein, which is subsequently cleaved into smaller products by viral-encoded cysteine proteinases [1,15]. Among these mature protein products are an RNA-dependent RNA polymerase (RdRp), an RNA helicase, and several putative RNA processing enzymes [19]. It is hypothesized that mature proteins must be newly translated and processed to function in viral RNA synthesis. Specifically, the addition of proteinase inhibitors at anytime during the MHV lifecycle abolishes viral RNA synthesis and halts replication [20]. These results, combined with the clinical and in vitro studies with proteinase inhibitors and SARS-CoV, suggest that the viral proteinases are principle targets for drug design. The determination of the crystal structure of the SARS-CoV main picornavirus 3C-like proteinase (3CLpro), facilitates the design of such drugs by elucidating determinants of inhibitor binding [21]. Moreover, a bioinformatics model of the catalytic core of the SARS-CoV RdRp has been proposed, allowing insight into the structure and function of this key viral enzyme during RNA synthesis [22]. Other important targets are proteins involved in the formation of membranous cytoplasmic viral replication complexes, which serve as scaffolds for the viral proteins to mediate RNA synthetic activities. Cells that have an engineered deletion of autophagy gene 5 (ATG 5) are unable form both autophagosomes as well as viral-induced double-membrane vesicles. These cells do not support efficient viral replication, suggesting that components of the cellular autophagy pathway can be targets for antiviral development [7].

The assembly and release of coronavirus virions from the host cell is the final stage of the viral lifecycle. Although the molecular determinants of coronavirus assembly and release are not well characterized, these processes represent additional targets for inhibition of replication. Following viral RNA synthesis in the cytoplasm, newly synthesized genome RNA molecules are transported to sites of virion particle assembly by an unknown mechanism. For MHV, virus assembly and budding occur in the endoplasmic-reticulum-Golgi intermediate compartment (ERGIC) [23]. Several MHV proteins, including the helicase and the nucleocapsid protein, also translocate to the ERGIC during times of particle assembly, and are thought to be involved in the delivery of the RNA to be packaged into newly budding virus [24]. Thus, inhibiting the capacity of helicase and nucleocapsid to deliver genomic RNA molecules to the ERGIC would probably hinder particle assembly. Trafficking of assembled coronaviruses to the cell surface where they are released is not well understood, but is presumed to occur through the normal exocytic processes.

**Summary and conclusions**

Although the SARS outbreak is now under control, the likelihood of possible human and animal reservoirs suggest that this virus will continue to pose a worldwide public health threat. Understanding the biology and pathogenesis of coronaviruses is crucial to the development of antivirals and therapeutics for potential intervention in the case of a SARS-CoV reemergence. Such drugs will probably target factors involved in the cellular destruction caused by viral replication, as well as factors influencing immune-mediated damage. Highest priority should be given to the development
of antivirals that will block SARS-CoV replication. Inhibitors of early steps in the virus lifecycle could block early- and mid-stage cytopathic effect and possibly decrease immunopathological damage observed in SARS-CoV-infected persons.

Since the last identified naturally occurring case of SARS in July 2003, remarkable progress has been made in studies to identify targets for interference with virus replication, to identify potential therapeutics for SARS-CoV, to develop animal models for replication and pathogenesis, and to test potential vaccine candidates. In a recent comprehensive study more than 10,000 natural and synthetic compounds were assayed for the capacity to inhibit SARS-CoV replication in cell culture [25]. This screen identified approximately 50 putative antivirals that are currently in clinical development, suggesting that a cure for SARS might be closer than once thought. But the question that remains is – should the development and testing of therapeutics and vaccines be sustained, because SARS appears to have retreated into its unknown endemic host and is not causing human disease? The answer to that question is yes, for several reasons. First, there have been isolated cases of SARS since July 2003, resulting from lab-associated infection, but also possibly from de novo transmission from animal to human. As the recent cases from China attest, the very characteristics of SARS-CoV that resulted in the worldwide epidemic are the same ones that is make it possible to reemerge, including a relatively long incubation period, nonspecific prodrome, and variably efficient transmission. Second, the natural host or mechanism for introduction and maintenance in humans is not known, and thus it is important to have strategies for implementation in the case of new outbreaks. Third, many of the strategies being tested have probably application to other coronaviruses of humans and animals, and thus are potentially important in their own right. Finally, there are discussions about SARS-CoV biosafety and biosecurity, both for inadvertent and possible intentional outbreaks. It is therefore essential to understand targets for therapeutics and to define strategies for prevention. In summary, the application of knowledge concerning the clinical manifestation of coronavirus disease and the molecular determinants of coronavirus replication will provide a foundation for the rapid development of effective inhibitors of these pathogenic viruses.

**Outstanding issues**

- How can we prevent or treat coronavirus diseases?
- How does damage to infected cells caused by coronavirus replication impact the severity of disease?
- What is the role of the host immune response in the pathogenesis of SARS-CoV?
- What are the molecular targets for inhibiting coronavirus replication?

**References**

1. Lai, M.M. (2003) SARS virus: the beginning of the unraveling of a new coronavirus. *J. Biomed. Sci. 10*, 664–675
2. Kuiken, T. et al. (2003) Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. *Lancet 362*, 263–270
3. Peiris, J.S. et al. (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet 361*, 1767–1772
4. Zhang, Q.L. et al. (2003) Detection of cell apoptosis in the pathological tissues of patients with SARS and its significance. *Di Yi Jun Yi Da Xue Xue Bao 23*, 770–773
5. Liu, Y. et al. (2003) Induction of caspase-dependent apoptosis in cultured rat oligodendrocytes by murine coronavirus is mediated during cell entry and does not require virus replication. *J. Virol. 77*, 11952–11963
6. Surjit, M. et al. (2004) The SARS coronavirus nucleocapsid (N) protein induces actin reorganization and apoptosis in COS-1 cells in the absence of growth factors. *Biochem. J. August 5 (epub ahead of print)
7. Prentice, E. et al. (2004) Coronavirus replication complex formation utilizes components of cellular autophagy. *J. Biol. Chem. 279*, 10136–10144
8. Ng, P.C. et al. (2004) Inflammatory cytokine profile in children with severe acute respiratory syndrome. *Pediatrics 113*, 7–14
9. Zhang, Y. et al. (2004) Analysis of serum cytokines in patients with severe acute respiratory syndrome. *Infect. Immun. 72*, 4410–4415
10. Rempelt, J.D. et al. (2004) Differential regulation of innate and adaptive immune responses in viral encephalitis. *Virology 318*, 381–392
11. Loufty, M.R. et al. (2003) Interferon alfalfa-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *J. Am. Med. Assoc. 290*, 3222–3228
12. Wong, V.W. et al. (2003) Treatment of severe acute respiratory syndrome with convalescent plasma. *Hong Kong Med. J. 9*, 199–201
13. Yount, B. et al. (2003) Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. *Proc. Natl. Acad. Sci. USA 100*, 12995–13000
14. Chu, C.M. et al. (2004) Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax 59*, 252–256
15. Thiel, V. et al. (2003) Mechanisms and enzymes involved in SARS coronavirus genome expression. *J. Gen. Virol. 84*, 2305–2355
16. Li, W. et al. (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature 426*, 450–454
17. Simmons, G. et al. (2004) Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. *Proc. Natl. Acad. Sci. USA 101*, 4240–4245
18. Tripet, B. et al. (2004) Structural characterization of the SARS-coronavirus spike S fusion protein core. *J. Biol. Chem. 279*, 20836–20849
19. Snijder, E.J. et al. (2003) Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. *J. Mol. Biol. 331*, 991–1004
20. Kim, J.C. et al. (1995) Coronavirus protein processing and RNA synthesis is inhibited by the cysteine proteinase inhibitor E64d. *Virology 208*, 1–8
21. Yang, H. et al. (2003) The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor. *Proc. Natl. Acad. Sci. USA 100*, 13190–13195
22. Xu, X. et al. (2003) Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. *Nucleic Acids Res. 31*, 7117–7130
23. Krijnse-Locker, J. et al. (1994) Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step. *J. Cell. Biol. 124*, 55–70
24. Bost, A.G. et al. (2001) Mouse hepatitis virus replicate protein complexes are translocated to sites of M protein accumulation in the ERGIC at late times of infection. *Virology 285*, 21–29
25. Wu, C.Y. et al. (2004) Small molecules targeting severe acute respiratory syndrome human coronavirus. *Proc. Natl. Acad. Sci. USA 101*, 10012–10017

www.drugdiscoverytoday.com